NO2498610T3 - - Google Patents

Info

Publication number
NO2498610T3
NO2498610T3 NO10830880A NO10830880A NO2498610T3 NO 2498610 T3 NO2498610 T3 NO 2498610T3 NO 10830880 A NO10830880 A NO 10830880A NO 10830880 A NO10830880 A NO 10830880A NO 2498610 T3 NO2498610 T3 NO 2498610T3
Authority
NO
Norway
Application number
NO10830880A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2498610(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2498610T3 publication Critical patent/NO2498610T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pest Control & Pesticides (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Agronomy & Crop Science (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10830880A 2009-11-13 2010-11-15 NO2498610T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056760 WO2011060392A1 (fr) 2009-11-13 2010-11-15 Modulateurs sélectifs du récepteur de sphingosine-1-phosphate et procédés de synthèse chirale

Publications (1)

Publication Number Publication Date
NO2498610T3 true NO2498610T3 (fr) 2018-08-11

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10830880A NO2498610T3 (fr) 2009-11-13 2010-11-15
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Country Status (31)

Country Link
US (4) US8362048B2 (fr)
EP (3) EP3406142B8 (fr)
JP (3) JP5650233B2 (fr)
KR (2) KR101721716B1 (fr)
CN (2) CN105061350B (fr)
AU (1) AU2010319983B2 (fr)
BR (2) BR122018077504B8 (fr)
CA (2) CA2986521C (fr)
CY (3) CY1120338T1 (fr)
DK (2) DK3406142T3 (fr)
EA (2) EA035768B1 (fr)
ES (2) ES2858337T3 (fr)
FR (1) FR20C1059I2 (fr)
HK (2) HK1213874A1 (fr)
HR (2) HRP20180874T1 (fr)
HU (3) HUE037535T2 (fr)
IL (2) IL219691B (fr)
LT (3) LT3406142T (fr)
LU (1) LUC00184I2 (fr)
MX (1) MX2012005560A (fr)
MY (2) MY161854A (fr)
NO (2) NO2498610T3 (fr)
NZ (1) NZ599915A (fr)
PH (1) PH12015502708B1 (fr)
PL (2) PL3406142T3 (fr)
PT (2) PT2498610T (fr)
RS (2) RS57253B1 (fr)
SG (1) SG10201407357PA (fr)
SI (2) SI2498610T1 (fr)
TR (1) TR201807912T4 (fr)
WO (1) WO2011060392A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986521C (fr) 2009-11-13 2020-06-30 Celgene International Ii Sarl Modulateurs selectifs du recepteur de sphingosine-1-phosphate et procedes de synthese chirale
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
WO2012158550A2 (fr) 2011-05-13 2012-11-22 Receptos, Inc. Modulateurs hétérocycliques sélectifs du récepteur de la sphingosine-1-phosphate
MX355261B (es) * 2012-06-21 2018-04-12 Eisai R&D Man Co Ltd Derivado de indanosulfamida novedoso.
WO2014158302A1 (fr) * 2013-03-25 2014-10-02 Swenson Rolf Eric Nouveaux antagonistes de récepteur de sphingosine 1-phosphate
WO2015066515A1 (fr) * 2013-11-01 2015-05-07 Receptos, Inc. Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
AU2016246398A1 (en) 2015-04-06 2017-10-26 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
CN109219597A (zh) * 2016-06-14 2019-01-15 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
JP6883882B2 (ja) * 2016-07-22 2021-06-09 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｓ１ｐ１アゴニスト及びその応用
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
WO2018050091A1 (fr) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 Forme cristalline du chlorhydrate de l'ozanimod et son procédé de préparation
JP7086945B2 (ja) * 2016-09-29 2022-06-20 レセプトス・リミテッド・ライアビリティ・カンパニー 狼瘡を処置するための化合物および方法
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
US20200031784A1 (en) * 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
WO2018208855A1 (fr) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Agonistes du récepteur de la sphingosine-1-phosphate utilisés dans la neuroprotection
WO2018215807A1 (fr) * 2017-05-22 2018-11-29 Egis Gyógyszergyár Zrt. Procédé de production d'ozanimod
CA3061201A1 (fr) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Composes modulant la voie de la sphingosine pour le traitement de cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
EP3677575A4 (fr) * 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline du chlorhydrate d'ozanimod et procédé de préparation correspondant
WO2019058290A1 (fr) * 2017-09-20 2019-03-28 Suven Life Sciences Limited Procédé amélioré pour la préparation d'un composé a-amino d'azanimod
WO2019094409A1 (fr) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Sels et formes à l'état solide d'ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
BR112020014488A2 (pt) * 2018-01-18 2020-12-01 Shijiazhuang Sagacity New Drug Development Company, Ltd. formas cristalinas e salinas do composto tricíclico e processo de preparação das mesmas
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
WO2020005313A1 (fr) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Composés modulant la voie de la sphingosine pour le traitement de cancers
EP3849965A1 (fr) 2018-09-12 2021-07-21 Pharmazell GmbH Procédé de préparation d'ozanimod et de son intermédiaire (s)-1-amino-2,3-dihydro-1h-indène-4-carbonitrile
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
ES2962211T3 (es) 2018-12-07 2024-03-18 Synthon Bv Proceso mejorado para preparar ozanimod
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
CN113891883A (zh) * 2019-03-29 2022-01-04 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
WO2020205481A1 (fr) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Modulateurs du récepteur de la sphingosine 1-phosphate
US20220227722A1 (en) * 2019-04-26 2022-07-21 Receptos Llc Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
WO2021009306A1 (fr) 2019-07-16 2021-01-21 Synthon B.V. Procédé amélioré de préparation d'ozanimod
EP4051250A1 (fr) 2019-10-31 2022-09-07 Idorsia Pharmaceuticals Ltd Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1
EP4087562A4 (fr) * 2020-01-06 2024-01-10 Arena Pharmaceuticals, Inc. Méthodes de traitement d'affections liées au récepteur de s1p1
US20230124301A1 (en) * 2020-03-04 2023-04-20 Helioeast Pharmaceutical Co., Ltd. Tricyclic compounds and use thereof
WO2021175223A1 (fr) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 Composé benzo 2-azaspiro[4,4]nonane et son utilisation
US11723895B2 (en) 2020-03-17 2023-08-15 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
US20230183194A1 (en) 2020-04-02 2023-06-15 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
WO2022213935A1 (fr) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 Composé spirocyclique substitué par oxadiazole et son application
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p
WO2023152767A1 (fr) 2022-02-11 2023-08-17 Mylan Laboratories Limited Formes polymorphes de chlorhydrate d'ozanimod

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0583346A1 (fr) 1991-04-12 1994-02-23 Schering Corporation Amides bicycliques de l'acyle-coenzyme a: cholesterol acyltransferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
WO1999037642A1 (fr) * 1998-01-23 1999-07-29 Sankyo Company, Limited Derives de spiropiperidine
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
SI3549936T1 (sl) 2003-04-11 2021-09-30 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
CN104324025A (zh) † 2005-08-03 2015-02-04 诺华股份有限公司 Hdac抑制剂在治疗骨髓瘤中的用途
WO2007033002A1 (fr) 2005-09-14 2007-03-22 Amgen Inc. Acides propanoïques 3-substitués par un groupement 4-hydroxyphényle à conformation contrainte pouvant être employés dans le traitement de troubles métaboliques
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
CA2634488C (fr) 2005-12-21 2016-10-04 Joseph Gabriele Proteines regulees par catecholamines
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8044076B2 (en) * 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106224A1 (fr) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Composés macrolides et procédés de fabrication et d'utilisation de ceux-ci
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (fr) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 Composé d’acides aminés
EP2913326B1 (fr) * 2008-05-14 2020-07-15 The Scripps Research Institute Nouveaux modulateurs de récepteurs de la sphingosine phosphate
US8485794B2 (en) * 2008-06-13 2013-07-16 Doowon Technical College Reciprocating compressor with rotary valve
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (fr) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Dérivés d'oxadiazole disubstitués utiles dans le traitement de troubles auto-immuns et inflammatoires
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
CA2986521C (fr) 2009-11-13 2020-06-30 Celgene International Ii Sarl Modulateurs selectifs du recepteur de sphingosine-1-phosphate et procedes de synthese chirale
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
PT2498609T (pt) 2009-11-13 2018-07-06 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato heterocíclico seletivo
WO2012158550A2 (fr) 2011-05-13 2012-11-22 Receptos, Inc. Modulateurs hétérocycliques sélectifs du récepteur de la sphingosine-1-phosphate
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Also Published As

Publication number Publication date
WO2011060392A1 (fr) 2011-05-19
LTPA2020533I1 (lt) 2020-12-10
BR112012011427B8 (pt) 2021-05-25
EP2498610B1 (fr) 2018-03-14
AU2010319983A2 (en) 2013-09-12
PH12015502708A1 (en) 2016-10-17
EP2498610A1 (fr) 2012-09-19
CA2780772A1 (fr) 2011-05-19
IL267956B (en) 2021-01-31
CA2986521C (fr) 2020-06-30
EA201690391A1 (ru) 2016-08-31
HUE037535T2 (hu) 2018-09-28
SG10201407357PA (en) 2014-12-30
NZ599915A (en) 2014-07-25
US20170320839A1 (en) 2017-11-09
CY2020035I2 (el) 2021-03-12
US10239846B2 (en) 2019-03-26
ES2673160T3 (es) 2018-06-20
KR101752124B1 (ko) 2017-06-28
KR20160149317A (ko) 2016-12-27
EP2498610B2 (fr) 2024-06-19
RS61829B1 (sr) 2021-06-30
IL219691A0 (en) 2012-07-31
EA024801B1 (ru) 2016-10-31
PH12015502708B1 (en) 2016-10-17
CN102762100A (zh) 2012-10-31
JP5982705B2 (ja) 2016-08-31
LTC2498610I2 (lt) 2022-06-10
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
KR101721716B1 (ko) 2017-04-10
CA2986521A1 (fr) 2011-05-19
JP2014122208A (ja) 2014-07-03
US20150299149A1 (en) 2015-10-22
JP5650233B2 (ja) 2015-01-07
CY1124121T1 (el) 2022-05-27
CN102762100B (zh) 2015-07-01
HRP20180874T1 (hr) 2018-07-13
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
LT2498610T (lt) 2018-06-11
US20110172202A1 (en) 2011-07-14
BR112012011427A2 (pt) 2015-10-06
AU2010319983A1 (en) 2012-05-31
ES2858337T3 (es) 2021-09-30
HUS2000045I1 (hu) 2020-12-28
MY161854A (en) 2017-05-15
HK1213874A1 (zh) 2016-07-15
EP2498610A4 (fr) 2013-05-22
PL3406142T3 (pl) 2021-08-30
EP3406142B8 (fr) 2021-03-03
CA2780772C (fr) 2018-01-16
PT3406142T (pt) 2021-03-26
PL2498610T3 (pl) 2018-08-31
SI3406142T1 (sl) 2021-08-31
BR122018077504B1 (pt) 2021-05-11
HK1175948A1 (en) 2013-07-19
BR112012011427B1 (pt) 2021-04-20
LT3406142T (lt) 2021-06-10
MX2012005560A (es) 2012-10-05
EP3406142A1 (fr) 2018-11-28
DK3406142T3 (da) 2021-03-22
EA201290323A1 (ru) 2013-05-30
AU2010319983B2 (en) 2015-03-12
EA035768B1 (ru) 2020-08-07
BR122018077504B8 (pt) 2021-05-25
NO2020039I1 (no) 2020-11-18
MY189750A (en) 2022-03-02
SI2498610T1 (en) 2018-07-31
FR20C1059I1 (fr) 2020-12-25
TR201807912T4 (tr) 2018-06-21
HUE054000T2 (hu) 2021-08-30
EP3406142B1 (fr) 2020-12-23
EP3868377A1 (fr) 2021-08-25
CY1120338T1 (el) 2019-07-10
US8362048B2 (en) 2013-01-29
JP2013510885A (ja) 2013-03-28
KR20120102704A (ko) 2012-09-18
CY2020035I1 (el) 2021-03-12
HRP20210446T1 (hr) 2021-05-14
US9388147B2 (en) 2016-07-12
FR20C1059I2 (fr) 2021-12-10
CN105061350B (zh) 2018-05-29
PT2498610T (pt) 2018-06-19
IL267956A (en) 2019-09-26
LUC00184I2 (fr) 2024-07-01
JP2015038145A (ja) 2015-02-26
DK2498610T3 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
FR20C1059I1 (fr)
BR112012012396A2 (fr)
BR112012008267A2 (fr)
BR112012003062A2 (fr)
BR112012008195A2 (fr)
BR112012000607A2 (fr)
BRPI0925311A2 (fr)
BR112012003080A2 (fr)
BR112012012487A2 (fr)
BR112012000665A2 (fr)
BR112012003853A2 (fr)
BR112012012080A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BR112012007656A2 (fr)
BR112012002627A2 (fr)
BR112012001263A2 (fr)
BR112012000159A2 (fr)
BR112012014856A2 (fr)
BR112012007654A2 (fr)
BR112012007672A2 (fr)
BR112012005951A2 (fr)
BR112012000255A2 (fr)